Alembic Pharmaceuticals has received final approval from the US Food Drug Administration USFDA for its Abbreviated New Drug Application ANDA for Cyclophosphamide Capsules 25 mg and 50 mg The approved ANDA is therapeutically equivalent to the reference listed drug product RLD Cyclophosphamide Capsules 25 mg and 50 mg of Hikma Pharmaceuticals USA Inc Cyclophosphamide Capsules is an alkylating drug indicated for the treatment of malignant disease and minimal change nephrotic syndrome in pediatric patients Cyclophosphamide Capsules 25 mg and 50 mg have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.